Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences
Orchestra BioMed (Nasdaq: OBIO) said company management will participate in multiple institutional investor conferences in late 2025. The company will hold one-on-one investor meetings at the 2025 Jefferies London Healthcare Conference on Nov 17-20, 2025, with meetings on Nov 18. Management will also appear at the Piper 37th Annual Healthcare Conference on Dec 2-4, 2025, including a live fireside chat on Dec 3 at 11:00am ET and additional one-on-one meetings.
The Piper presentation will be available via live webcast and replay on Orchestra BioMed’s Investor Relations website for investors and interested parties.
Orchestra BioMed (Nasdaq: OBIO) ha detto che la direzione dell'azienda parteciperà a numerose conferenze per investitori istituzionali entro la fine del 2025. L'azienda terrà riunioni individuali con gli investitori alla 2025 Jefferies London Healthcare Conference dal 17 al 20 novembre 2025, con incontri il 18 novembre. La direzione parteciperà anche alla Piper 37th Annual Healthcare Conference dal 2 al 4 dicembre 2025, inclusa una chat informale dal vivo intorno al fuoco il 3 dicembre alle 11:00 ET e ulteriori incontri individuali. La presentazione Piper sarà disponibile in live webcast e in replay sul sito Investitori di Orchestra BioMed per investitori e interessati.
Orchestra BioMed (Nasdaq: OBIO) dijo que la dirección de la empresa participará en múltiples conferencias de inversores institucionales a finales de 2025. La empresa llevará a cabo reuniones individuales con inversionistas en la Conferencia de Salud de Jefferies Londres 2025 del 17 al 20 de noviembre de 2025, con reuniones el 18 de noviembre. La dirección también asistirá a la 37ª Conferencia Anual de Salud Piper del 2 al 4 de diciembre de 2025, incluida una charla informal en vivo junto a la chimenea el 3 de diciembre a las 11:00 a. m. ET y más reuniones individuales. La presentación de Piper estará disponible vía webcast en vivo y en reproducción en el sitio web de Relaciones con Inversores de Orchestra BioMed para inversores y partes interesadas.
Orchestra BioMed (Nasdaq: OBIO)은 회사 경영진이 2025년 말 다수의 기관 투자자 회의에 참석할 것이라고 밝혔다. 회사는 2025 Jefferies London Healthcare Conference에서 2025년 11월 17-20일 사이에 일대일 투자자 미팅을 개최하며 11월 18일에 회의를 진행할 예정이다. 경영진은 또한 Piper 37th Annual Healthcare Conference에 2025년 12월 2-4일에 참석하고, 12월 3일 11:00am ET에 라이브 무릎-거의? 라이브 차임크? 라이브 화상 대담을 포함하고 추가적인 일대일 미팅이 있다. Piper 발표는 라이브 생중계 및 재방송으로 Orchestra BioMed의 투자자 관계 웹사이트에서 투자자 및 관심 있는 사람들이 이용 가능하다.
Orchestra BioMed (Nasdaq : OBIO) a déclaré que la direction de l'entreprise participera à plusieurs conférences d'investisseurs institutionnels fin 2025. L'entreprise tiendra des entretiens individuels avec des investisseurs lors de la 2025 Jefferies London Healthcare Conference du 17 au 20 novembre 2025, avec des rencontres le 18 novembre. La direction assistera également à la Piper 37th Annual Healthcare Conference du 2 au 4 décembre 2025, y compris une session de discussion informelle au coin du feu en direct le 3 décembre à 11h00 ET et d'autres entretiens individuels. La présentation Piper sera disponible en direct via webcast et en replay sur le site des relations investisseurs d'Orchestra BioMed pour les investisseurs et les parties intéressées.
Orchestra BioMed (Nasdaq: OBIO) sagte, dass das Unternehmensmanagement an mehreren Konferenzen für institutionelle Investoren Ende 2025 teilnehmen werde. Das Unternehmen wird bei der 2025 Jefferies London Healthcare Conference vom 17. bis 20. November 2025 einzelne Investorengespräche führen, mit Treffen am 18. November. Das Management wird außerdem bei der Piper 37th Annual Healthcare Conference vom 2. bis 4. Dezember 2025 auftreten, einschließlich eines Live-Fireside-Chats am 3. Dezember um 11:00 Uhr ET und weiterer Einzelgespräche. Die Piper-Präsentation wird per Live-Webcast und Wiedergabe auf der Investor-Relation-Website von Orchestra BioMed für Investoren und Interessierte verfügbar sein.
Orchestra BioMed (ناسداك: OBIO) قالت إن إدارة الشركة ستشارك في عدة مؤتمرات للمستثمرين المؤسساتيين في أواخر 2025. ستعقد الشركة اجتماعات فردية مع المستثمرين في مؤتمر Jefferies London Healthcare 2025 من 17 إلى 20 نوفمبر 2025، مع اجتماعات في 18 نوفمبر. كما ستحضر الإدارة في Piper 37th Annual Healthcare Conference من 2 إلى 4 ديسمبر 2025، بما في ذلك دردشة حية بجوار المدفأة في 3 ديسمبر الساعة 11:00 صباحاً بتوقيت شرق الولايات المتحدة وإجراء اجتماعات فردية إضافية. ستكون عرض Piper متاحاً عبر البث المباشر وإعادة التشغيل على موقع علاقات المستثمرين لشركة Orchestra BioMed للمستثمرين والمهتمين.
- None.
- None.
NEW HOPE, Pa., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, today announced that company management will participate in multiple upcoming institutional investor conferences. Details on the Company’s participation appear below:
2025 Jefferies London Healthcare Conference – November 17-20, 2025 (London, UK)
Management will host one-on-one meetings with investors on Tuesday, November 18.
Piper 37th Annual Healthcare Conference – December 2-4, 2025 (New York, NY)
Management will participate in a live fireside chat with Matthew O’Brien, Senior Research Analyst at Piper Sandler at 11:00am ET on Wednesday, December 3 and will also host one-on-one meetings with investors. The event will be accessible to investors and interested parties via a live webcast, which will be available live via this link, as well as after the event on Orchestra BioMed’s Investor Relations website.
About Orchestra BioMed
Orchestra BioMed is a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations with market-leading global medical device companies. The Company’s two flagship product candidates - Atrioventricular Interval Modulation (AVIM) Therapy and Virtue® Sirolimus AngioInfusion™ Balloon (Virtue SAB) - are currently undergoing pivotal clinical trials for their lead indications, each representing multi-billion-dollar annual global market opportunities. AVIM Therapy is a bioelectronic treatment for hypertension, the leading risk factor for death worldwide, and is designed to be delivered as a firmware upgrade to a pacemaker and achieve immediate, substantial and sustained reductions in blood pressure in patients with hypertensive heart disease. The Company has a strategic collaboration with Medtronic (NYSE: MDT), one of the largest medical device companies in the world, for the development and commercialization of AVIM Therapy for the treatment of uncontrolled hypertension in pacemaker-indicated patients. AVIM Therapy has FDA Breakthrough Device Designation for these patients, as well as an estimated 7.7 million total patients in the U.S. with uncontrolled hypertension despite medical therapy and increased cardiovascular risk. Virtue SAB is a highly differentiated, first-of-its-kind drug delivery angioplasty balloon system designed to deliver a proprietary extended-release formulation of sirolimus, SirolimusEFR™, for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. Virtue SAB has been granted Breakthrough Device Designation by the FDA for the treatment of coronary ISR, coronary small vessel disease and below-the-knee peripheral artery disease. For further information about Orchestra BioMed, please visit www.orchestrabiomed.com, and follow us on LinkedIn.
Investor Contact:
Silas Newcomb
Orchestra BioMed
Snewcomb@orchestrabiomed.com
Media Contact:
Kelsey Kirk-Ellis
Orchestra BioMed
kkirkellis@orchestrabiomed.com
FAQ
When will Orchestra BioMed (OBIO) present at the Jefferies London Healthcare Conference 2025?
What time is Orchestra BioMed's (OBIO) Piper conference fireside chat on Dec 3, 2025?
Will Orchestra BioMed's (OBIO) Piper conference presentation be available online?
Can investors meet Orchestra BioMed (OBIO) management one-on-one at these conferences?
Where can I find the webcast replay of Orchestra BioMed's (OBIO) Piper presentation after Dec 3, 2025?
